Analysts Are Bullish on These Healthcare Stocks: Rigel (RIGL), Opus Genetics (IRD)
TipRanks (Tue, 8-Sep 6:30 AM ET)
Rigel to Participate in Upcoming September Investor Conferences
PRNewswire (Wed, 2-Sep 8:05 AM ET)
PRNewswire (Thu, 13-Aug 8:05 AM ET)
Rigel Reports Second Quarter 2026 Financial Results
PRNewswire (Tue, 4-Aug 4:01 PM ET)
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
PRNewswire (Tue, 28-Jul 8:05 AM ET)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PRNewswire (Tue, 7-Jul 8:05 AM ET)
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
PRNewswire (Wed, 1-Jul 8:05 AM ET)
Rigel Announces Closing of Licensing Agreement for VEPPANU (vepdegestrant)
PRNewswire (Tue, 16-Jun 4:01 PM ET)
Rigel’s VEPPANU Approval Marks Significant Step for ESR1-Mutated Breast Cancer
Market Chameleon (Tue, 12-May 3:36 AM ET)
Rigel Delivers Record Sales and Net Income Surge in Q3 2025, Raises Revenue Guidance
Market Chameleon (Wed, 5-Nov 5:32 AM ET)
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Rigel Pharmaceuticals trades on the NASDAQ stock market under the symbol RIGL.
As of September 9, 2026, RIGL stock price declined to $47.01 with 5,792 million shares trading.
RIGL has a beta of 1.06, meaning it tends to be more sensitive to market movements. RIGL has a correlation of 0.05 to the broad based SPY ETF.
RIGL has a market cap of $869.78 million. This is considered a Small Cap stock.
Last quarter Rigel Pharmaceuticals reported $79 million in Revenue and $.88 earnings per share. This beat revenue expectation by $20 million and exceeded earnings estimates by $.71.
In the last 3 years, RIGL traded as high as $52.24 and as low as $7.12.
The top ETF exchange traded funds that RIGL belongs to (by Net Assets): AVUV, XBI, VTI, VXF, SCHA.
RIGL has underperformed the market in the last year with a return of +15.0%, while SPY returned +18.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in RIGL shares. However, RIGL has outperformed the market in the last 3 month and 2 week periods, returning +56.3% and +0.6%, while SPY returned +3.6% and -0.3%, respectively. This indicates RIGL has been having a stronger performance recently.
RIGL support price is $45.99 and resistance is $48.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RIGL shares will trade within this expected range on the day.
